Author: Afrose, Fahmida ; Rahman, Abdur ; Pathak, Rashmi ; Sayem, Ali Awsaf ; Nabin, Md. Naimur Rahman ; Islam, Md. Hasibul ; Tanme, Tahia Akter ; Al Noman, Abdullah ; Hosen, Md. Raiyan ; Fahima, Kaniz ; Sejuti, Shahrin Raisa ; Sharma, Himanshu ; Anuva, Nayeema Jameel ; Noman, Md Jahidul Islam

This study aims to provide clinical and scientific information about the effects of various anti-inflammatory medicines on patients with cardiovascular disease (CVD). We also discussed the anti-inflammatory strategies and molecular mechanisms being investigated in preclinical or clinical CVD research. Numerous studies on anti-inflammatory medicines for CVD have resulted from greater knowledge of how innate and adaptive immunity influence plaque development and rupture. Some of these are now being evaluated in clinical trials and use lower dosages of existing medications that were initially developed for other inflammatory disorders with a high risk of CVD, such as rheumatoid arthritis and psoriasis. Other research includes retrospective and meta-analyses of clinical trials that examine the risk of CVD among individuals with various inflammatory diseases. We also included natural bioactive compounds, nanodrug and multiomics approaches to treat CVD by utilizing inflammatory pathways. Chronic subclinical inflammation is a major contributor to the development of CVD and has been associated with both the onset and progression of atherosclerosis. Several pro-inflammatory cytokines, including C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukins-1 and 6 (IL-1 and IL-6), leukotrienes, and adiponectin, have been identified as independent risk factors for coronary heart disease and promoters of arterial development. Researchers are looking for ways to stop the different inflammatory pathways that lead to atherosclerosis. These include multiomics approach, antioxidants, phospholipase A2 inhibitors, leukotriene pathway inhibitors, Phospholipase A2 (PLA2) inhibitors, non-inhibitors anti-inflammatory drugs (like methotrexate), IL-1 inhibitors, and p-selectin inhibitors.

01 Feb 2025·Heliyon

Towards carbon neutrality & COP29 Baku / Azerbaijan - COP30 Belem / Brazil: Exploring the impacts of economic, environmental, social, and governance (ECON-ESG) factors on Climate Policy Uncertainty (CPU) for sustainable development

Article

Author: Yan, Jiale ; Islam, Hasibul ; Ongan, Serdar ; Işık, Cem

Climate policy is crucial in shaping global responses to environmental challenges and steering societies towards sustainable and resilient futures. Thus, in research study, we examine the impacts of Economic (ECONF), Environmental (ENVF), Social (SOCF), and Governance (GOVNF) factors, as well as the combined (ECON-ESG) factors, on Climate Policy Uncertainty (CPU) at the global level. The new ECON-ESG form of sustainability, defined in this study, refers to the holistic approach to sustainability by including economic factors (ECON) to traditional ESG factors. Empirical findings reveal that while environmental (E) and social (S) factors worsen the CPU, economic factors (ECON) improve it in the long run. Governance (G) factors have no impact on the CPU. While a 1 % increase in E and S increases the CPU by 22 % and 27 %, the same percentage increase in ECON decreases it by 40 %. These results clearly show that analyses conducted only through the conventional form of ESG may be insufficient and inaccurate in analyzing the effects on the CPU. Our study's result should not be considered limited to the CPU only, and it will be helpful to use this proposed form, ECON-ESG, as a more comprehensive sustainability concept in sustainability studies since it also incorporates economic factors. This approach will enable policymakers to look at climate policies through a holistic sustainability lens with ECON-ESG. These results show that policymakers should adopt a holistic sustainability approach that includes economic factors when shaping climate policies.

11 Jan 2025·2025 4th International Conference on Robotics, Electrical and Signal Processing Techniques (ICREST)

Delta/Fork Transformer Based 30-Pulse Star Rectifier for Input Current Harmonic Reduction

Author: Islam, Md. Zahidul ; Malek, Md. Abdul ; Goffar Khan, Muhammad Abdul ; Tahmid, Mahbubur Rahman

100 Deals associated with Varendra University

100 Translational Medicine associated with Varendra University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 12 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Varendra University

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 12 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing